產品
重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。
已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。
標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。
經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。
涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。
閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。
10月13日週二 · 今天
10月14日週三
8月31日週一
產品
監管
產品
Walmart is turning to a lottery to allocate Pokemon trading cards as the trading-card supply debacle continues.
Pokémon Scalpers The Pokémon Company Walmart By John Walker Published August 31, 2026 | Comments ( 13 ) | 𝕏 Copied! Some Pokémon packs in front of a Walmart. © Shutterstock / Sundry Photography / The Pokémon Company / Kotaku As the Pokémon TCG approaches two full years of ridiculous shortages , beginning with November 2024’s Surging Sparks and growing worse ever since, retail stores are looking for novel ways to try to cope with the crisis. We’ve seen the full gamut, with some chains looking to do their best to prevent scalping and others just turning into scalpers themselves, whi…
產品
Drug Discovery Trends reports that the Merck and Moderna cancer vaccine is customized to each individual patient's tumor.
A new investigational cancer vaccine developed by Merck & Co. and Moderna is customized based on the genome of each patient’s tumor, designed to teach their immune system to recognize the cancer as a foreign body. The companies are investigating the vaccine as a combination treatment with Merck’s Keytruda, a monoclonal antibody that targets the PD-1 receptor on T-cells, breaking a pathway that cancer uses to evade the immune system. The FDA granted the combination Breakthrough Therapy designation in 2023 and the companies noted that they plan to engage with regulators to pursue app…
8月30日週日
監管
Yahoo Finance examines what Moderna's recent FDA vaccine approvals mean for the company's respiratory vaccine push.
What Do Moderna (MRNA) FDA Vaccine Approvals Mean For Its Respiratory Push? Bailey Pemberton Sun, August 30, 2026 at 1:09 PM GMT+10 3 min read MRNA Moderna (NasdaqGS:MRNA) received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant. The FDA also cleared mFlusiva, Moderna's first mRNA based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark the first FDA authorized mRNA flu shot for older adults. To see how other companies in this space are using similar technology, ex…